Vera Therapeutics is trading 4.3% higher at $31.35, with investors potentially positioning ahead of the October 22 webcast on final ORIGIN 3 results. - Results are scheduled for a late-breaking presentation at ASN Kidney Week; the webcast covers TRUTAKNA in IgA nephropathy, and Vera announced it October 20. - No company announcement on October 21 directly confirms why shares are rising. - Biotech-sector strength may also support shares: XBI is up 2.10%, while the broader market is higher.